December 2024 in “Journal of Cosmetic Dermatology” This study found that oral minoxidil was more likely to be associated with pericardial effusion compared to other adverse effects, with the relationship appearing dose independent.
9 citations
,
August 2024 in “Journal of Drugs in Dermatology” In this study, researchers found no evidence of increased prevalence of pericardial effusions in alopecia patients treated with low-dose oral minoxidil compared to those not receiving minoxidil, based on point-of-care ultrasound evaluations.
June 2024 in “Dermatology and therapy” This review suggests that low-dose oral minoxidil may be a safe option for treating hair disorders in children, while moderate and high doses may not be safe.
June 2023 in “Dermatologic Surgery” This review highlights the promising potential of mesotherapy for delivering dutasteride and minoxidil as treatments for androgenetic alopecia, emphasizing the need for more research on drug preparation, delivery, and maintenance to establish its safety and effectiveness.
August 2022 in “International Journal of Dermatology” In this study, low-dose oral minoxidil and sublingual minoxidil were generally well-tolerated in children with alopecia, with mild hypertrichosis as the most common adverse event.
August 2022 in “Journal of The American Academy of Dermatology” This study observed a slight reduction in blood pressure in normotensive patients after taking a 5-mg dose of oral minoxidil, particularly within the first two hours and more so in those with high baseline blood pressure.
3 citations
,
August 2022 in “JAAD case reports” This review discusses the emerging evidence for low-dose oral minoxidil in treating various types of alopecia, without providing new clinical results.
2 citations
,
July 2022 in “Frontiers in Medicine” This study found that combining topical minoxidil with microneedling improved hair density more than either minoxidil alone or with spironolactone for women with mild-to-moderate female pattern hair loss.
3 citations
,
May 2022 in “Journal of The American Academy of Dermatology” This source notes that while low-dose oral minoxidil is effective for treating androgenetic alopecia, it has been associated with electrocardiogram changes and palpitations even at low doses.
6 citations
,
April 2022 in “Journal of The American Academy of Dermatology” In this study, low-dose oral minoxidil was found to improve hair density in 80% of pediatric patients with androgenetic alopecia or telogen effluvium, with mild side effects primarily reported.
5 citations
,
August 2021 in “Journal of The European Academy of Dermatology and Venereology” In this phase 1B clinical trial, sublingual minoxidil was tested for its effects on male and female pattern hair loss in a randomized, double-blind, placebo-controlled setting, but the abstract does not provide specific results or conclusions.
1 citations
,
June 2021 in “Journal of Cosmetic Dermatology” In this study, the addition of a SULT1A1 enzyme booster to daily 5% minoxidil treatment significantly increased hair regrowth in men with androgenic alopecia compared to minoxidil alone.
4 citations
,
May 2021 in “Lasers in Surgery and Medicine” This study observed that adding low-level light therapy with the GentleWaves® device to Minoxidil significantly boosted hair regrowth in men with androgenetic alopecia by reducing scalp inflammation.
21 citations
,
March 2021 This study reviewed the literature on low-dose oral minoxidil as a primary treatment for various hair loss disorders, concluding that it is a successful and well-tolerated alternative to topical minoxidil for patients with poor adherence to other therapies.
3 citations
,
February 2021 in “Medical journal, Armed Forces India” In this observational study, the combination of PRP and 5% minoxidil was more effective than minoxidil alone in promoting hair growth in men with androgenetic alopecia.
39 citations
,
February 2021 in “Journal of The American Academy of Dermatology” In this study, low-dose oral minoxidil for hair loss was associated with infrequent systemic adverse effects, and only 1.7% of patients discontinued treatment due to these effects.
5 citations
,
December 2020 in “Journal of The American Academy of Dermatology” This study observed objective improvement in androgenetic alopecia in 5 out of 6 adolescent girls treated with 2.5 mg oral minoxidil and spironolactone, and reported no adverse effects.
7 citations
,
November 2020 in “Journal of The American Academy of Dermatology” This study found that low-dose oral minoxidil for androgenetic alopecia was associated with a higher incidence of hypertrichosis and edema compared to previous studies, but it remains a generally well-tolerated treatment option.
9 citations
,
October 2020 in “Journal of The American Academy of Dermatology” This letter discusses the limited adaptation of low dose oral minoxidil for androgenetic alopecia in North America and reports no new clinical results; the authors suggest safety concerns or unclear dosing may be factors.
7 citations
,
September 2020 in “Journal of The American Academy of Dermatology” This article describes the characteristics and management of hypertrichosis induced by low-dose oral minoxidil used for hair disorders, but reports no new clinical findings.
19 citations
,
June 2020 in “International Journal of Dermatology” In this systematic review, oral minoxidil was found to be a safe and effective treatment for androgenetic alopecia and alopecia areata, with additional benefits for female pattern hair loss and other types of alopecia, although common side effects included hypertrichosis and postural hypotension.
4 citations
,
June 2020 in “BMC Ophthalmology” This case report suggests that prolonged use of topical minoxidil for androgenic alopecia may cause central serous chorioretinopathy, and oral eplerenone appeared effective in resolving symptoms in the patient presented.
8 citations
,
April 2020 in “Journal of The American Academy of Dermatology” This report describes nine women who were allergic to topical minoxidil but successfully tolerated low-dose oral minoxidil without significant adverse effects, suggesting it may be a viable alternative for those with similar allergies.
53 citations
,
August 2019 in “Journal of The American Academy of Dermatology” This study observed that low-dose oral minoxidil and topical minoxidil 5% solution both improved hair density in women with female-pattern hair loss, but oral minoxidil may offer advantages in reducing hair shedding.
8 citations
,
August 2019 in “Journal of The American Academy of Dermatology” This study found that androgenetic alopecia is a significant yet under-recognized cause of hair loss in children and adolescents, often linked to family history and typically diagnosed by clinical examination.
32 citations
,
January 2019 in “American Journal of Clinical Dermatology” This review discusses the use of topical minoxidil for various types of alopecia and reports mixed evidence on its efficacy, with stronger support noted for conditions like eyebrow hypotrichosis and chemotherapy-induced alopecia.
8 citations
,
October 2018 in “Dermatologic Therapy” In this study of Indian patients with pattern hair loss, 40.8% showed low sulfotransferase enzyme activity in hair follicles, with a higher prevalence of low activity in men compared to women.
12 citations
,
September 2018 in “Dermatologic Therapy” This study found that 14 days of low-dose aspirin reduced the predicted response to topical minoxidil in androgenetic alopecia patients from 50% to 27%, suggesting aspirin may inhibit minoxidil efficacy.
16 citations
,
February 2017 in “Dermatology and Therapy” This study established and validated a visual scale to assess hair shedding in women with thick hair, finding it effective in distinguishing greater hair loss among women with female pattern hair loss compared to those without.
13 citations
,
June 2016 in “Dermatologic Therapy” This study found that minoxidil applied to a damp scalp may increase drug penetration in vitro, potentially improving treatment effectiveness.
32 citations
,
April 2015 in “British Journal of Dermatology” This article discusses hair shedding in women and does not offer new research results; it highlights the need for objective criteria to define excessive hair shedding.
19 citations
,
September 2014 in “British Journal of Dermatology” This study found that topical minoxidil 5% foam was effective in promoting hair growth in both the frontal and vertex scalp for men with androgenetic alopecia.
12 citations
,
March 2013 This report describes a case where a 4-year-old boy with congenital alopecia due to hypohidrotic ectodermal dysplasia experienced significant hair growth after using topical minoxidil.
9 citations
,
September 2011 in “Cutaneous and Ocular Toxicology” This article presents a case of central serous chorioretinopathy occurring after the use of topical minoxidil solution, but reports no clinical study findings.
142 citations
,
August 2007 in “Journal of The American Academy of Dermatology” This study found that a new 5% minoxidil foam formulation significantly increased hair counts and improved hair loss condition in men with androgenetic alopecia over 16 weeks compared to placebo.
58 citations
,
January 2007 in “Dermatology” Minoxidil use in children may cause heart issues.
37 citations
,
July 2005 in “Journal of The American Academy of Dermatology” This article reviews the clinicopathologic features of short anagen syndrome in a child and suggests diagnostic methods like clinical examination and scalp hair growth rate measurement, without reporting new clinical results.
219 citations
,
March 2004 in “Journal of The American Academy of Dermatology” In this 48-week trial, 5% topical minoxidil was more effective than both 2% minoxidil and placebo in promoting hair growth in women with female pattern hair loss, with notable improvements in nonvellus hair count and hair growth assessments.
397 citations
,
February 2004 in “British Journal of Dermatology” This article reviews the mechanisms by which minoxidil stimulates hair growth and reports no new clinical findings.
41 citations
,
June 2003 in “Journal of The American Academy of Dermatology” This case report describes a patient who developed pseudoacromegaly from long-term use of high-dose minoxidil, marking the first such documented case.
63 citations
,
April 2003 in “Journal of The European Academy of Dermatology and Venereology” This study found that minoxidil topical solution was associated with a dose-related occurrence of hypertrichosis, especially facial hair, in women treated for androgenetic alopecia.
269 citations
,
August 2002 in “Journal of The American Academy of Dermatology” This study found that 5% topical minoxidil significantly increased hair regrowth and improved psychosocial perceptions of hair loss in men with androgenetic alopecia compared to 2% topical minoxidil and placebo over 48 weeks.
84 citations
,
April 2002 in “Archives of Dermatology” This study found that a keratin mutation may cause diffuse partial woolly hair associated with loose anagen hair syndrome in some families, but other genetic factors could play a role in different cases.
127 citations
,
July 1996 in “Journal of The American Academy of Dermatology” This study found that in women undergoing chemotherapy after breast surgery, topical minoxidil significantly shortened the duration of hair loss compared to a placebo without significant side effects.
82 citations
,
March 1994 in “Archives of Dermatology” This study found that a 2% topical minoxidil solution significantly increased hair regrowth compared to placebo in women with androgenetic alopecia over 32 weeks.
58 citations
,
October 1993 in “International Journal of Dermatology” This study found that 2% topical minoxidil solution was significantly more effective than placebo in promoting new hair growth in women with androgenetic alopecia.
42 citations
,
July 1993 in “Journal of Investigative Dermatology”
166 citations
,
November 1990 in “Journal of Investigative Dermatology” Minoxidil sulfate stimulates hair growth.
25 citations
,
June 1990 in “Journal of Pharmaceutical Sciences” This study found that minoxidil absorption through the skin increased with longer contact times, reaching over 75% of the maximum absorption within four hours.
70 citations
,
April 1990 in “Journal of The American Academy of Dermatology” Minoxidil treatment increased hair growth for up to 5 years, requiring twice daily application.
30 citations
,
April 1990 in “Clinical Pharmacology & Therapeutics” This study found that coadministering minoxidil with tretinoin cream increased minoxidil absorption nearly threefold in healthy males, attributed to increased stratum corneum permeability.
4 citations
,
July 1987 in “Dermatologic Clinics”
57 citations
,
July 1987 in “Journal of The American Academy of Dermatology” In this study, minoxidil treatment was associated with an increase in nonvellus scalp hairs, but this effect was not sustained once the treatment was stopped.
104 citations
,
March 1987 in “Journal of The American Academy of Dermatology” Minoxidil helps hair growth in 63.6% of alopecia patients, with 27.3% having excellent results.
51 citations
,
March 1987 in “Journal of The American Academy of Dermatology” This study found that twice-daily application of 3% topical minoxidil maintained a higher nonvellus hair count compared to once-daily application over 2 years and 9 months in men with male pattern baldness.
19 citations
,
January 1987 in “Dermatology” This review discusses the effects of minoxidil on human skin fibroblasts, reporting its potential to inhibit lysyl hydroxylase activity and DNA synthesis, suggesting it may have antifibrotic applications for collagen-related skin conditions.
58 citations
,
July 1986 in “Journal of The American Academy of Dermatology” Lowest effective minoxidil concentration is 1%, but 2% works better for male pattern baldness.
138 citations
,
August 1985 in “Journal of The American Academy of Dermatology” Minoxidil promotes hair growth in male pattern baldness.
52 citations
,
February 1985 in “Archives of Dermatology” Minoxidil absorbs poorly through skin, with low risk of side effects at 1-2% concentration.
45 citations
,
January 1981 in “Annals of Internal Medicine” Minoxidil controls blood pressure effectively, but may cause side effects like hypertrichosis.